Boenning & Scattergood, Inc. Uni Qure N.V. Transaction History
Boenning & Scattergood, Inc.
- $622 Million
- Q4 2022
A detailed history of Boenning & Scattergood, Inc. transactions in Uni Qure N.V. stock. As of the latest transaction made, Boenning & Scattergood, Inc. holds 20,000 shares of QURE stock, worth $302,200. This represents 0.06% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$302,200
Previous $375,000
3.73%
% of portfolio
0.06%
Previous 0.08%
Shares
2 transactions
Others Institutions Holding QURE
# of Institutions
178Shares Held
50.7MCall Options Held
2.13MPut Options Held
480K-
Vestal Point Capital, LP New York, NY4.79MShares$72.4 Million3.63% of portfolio
-
Rtw Investments, LP New York, NY4.27MShares$64.5 Million0.74% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.99MShares$60.3 Million3.32% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.76MShares$41.6 Million1.32% of portfolio
-
Abrdn PLC2.22MShares$33.5 Million0.05% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $706M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...